Trifarotene Patent Expiration
Trifarotene is Used for treating acne vulgaris by activating RARgamma receptor topically. It was first introduced by Galderma Laboratories Lp
Trifarotene Patents
Given below is the list of patents protecting Trifarotene, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Aklief | US9084778 | Topical compositions containing a retinoid of the oil-in-water emulsion type | May 30, 2033 | Galderma Labs Lp |
| Aklief | US9498465 | Topical compositions in the form of a gel containing a particular solubilized retinoid | May 30, 2033 | Galderma Labs Lp |
| Aklief | US7807708 | Ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof | Jul 19, 2031 | Galderma Labs Lp |
| Aklief | US8227507 | Ligands that modulate RAR receptors | Dec 21, 2025 | Galderma Labs Lp |
| Aklief | US8470871 | Ligands that modulate RAR receptors | Dec 21, 2025 | Galderma Labs Lp |
Trifarotene's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List